Jaquel Patterson, ND, MBA, FMCP-M                       

Emerging research links pathogens such as Epstein-Barr virus, SARS-CoV-2, Lyme disease, and other infections to autoimmune disease through molecular mimicry, chronic inflammation, and immune dysregulation. This review explores the underlying mechanisms, recommended laboratory evaluation, and integrative strategies to restore immune tolerance and long-term health. 

Can an infection years earlier set the stage for autoimmune disease? This evidence-based review examines how post-infectious immune dysfunction may contribute to conditions such as multiple sclerosis, Hashimoto’s thyroiditis, rheumatoid arthritis, and lupus, while outlining a functional medicine approach to identifying infectious triggers, correcting nutritional deficiencies, supporting gut health, and restoring immune balance. 

In naturopathic practice, the most important part of an autoimmune patient’s history is often the part everyone else has ignored. The mononucleosis in her twenties, the tick bite that never seemed to amount to anything, the intestinal infection abroad, the COVID case that “resolved” but never really let go; these get filed as unrelated events. By the time a diagnosis lands, no one is looking backward at the infections that may have set it in motion.

But that’s frequently where the story begins. Autoimmune disease isn’t random or unlucky; it’s what happens when genetics, environment, and immune dysregulation accumulate over years, with an infection often serving as the trigger that pushes a susceptible patient into overt illness. More than hundred autoimmune conditions are now recognized, and nearly all of them have been tied to at least one infectious agent capable of initiating or worsening the process (Suliman, 2024). What’s changed recently is the strength of the evidence: the link has moved from plausible theory to some of the most compelling causal data in the field, most dramatically for Epstein-Barr virus and multiple sclerosis, and, since 2020, for SARS-CoV-2. Once you understand how a past infection becomes present autoimmunity, we can stop chasing lab markers and start treating the root cause.

How an Infection Breaks Tolerance

The immune system runs on one deceptively simple job: telling self from non-self. The innate response is the fast, non-specific first wave (phagocytes, natural killer cells, interferons, complement). The adaptive response is slower but precise: T cells that target the pathogen, B cells that make antibodies, and memory cells that remember the encounter. Autoimmunity is what happens when that job fails, and an infection can be exactly what breaks it (Suliman, 2024).

The mechanism that comes up most is molecular mimicry. When a pathogen carries antigens that look like our own proteins, the immune response built to fight the invader can turn and cross-react with the body’s own tissue, one of the leading ways infectious or chemical agents induce autoimmunity in a susceptible person (Suliman, 2024). And mimicry is almost never the whole story; genetics, prior microbial exposures, and toxic burden all decide whether that cross-reaction becomes self-sustaining (Suliman, 2024). Two other mechanisms pile on. In bystander activation, the inflammatory fire from an infection wakes up self-reactive immune cells nearby. In epitope spreading, tissue damage exposes self-antigens that were previously hidden, and the immune assault widens over time (Suliman, 2024). Underneath all of it is inflammation:  IL-1, IL-6, and TNF-α, driven through the NF-κB pathway. When the insult clears, the fire goes out. When it doesn’t, it turns chronic, and chronic inflammation drives disease.

Epstein-Barr Virus: From Association to Cause

If I had to point to one pathogen that makes this model concrete, it’s Epstein-Barr virus. Most of the population carries EBV, usually from childhood; catch it as a teen or young adult and it often shows up as mononucleosis. After the acute infection, the virus doesn’t leave and it settles into lifelong latency in B cells, and that persistence is what ties it to autoimmunity.

The evidence took a decisive turn with a landmark study in Science. Following serial serum samples from more than ten million U.S. military personnel, 955 of whom developed multiple sclerosis, researchers found the risk of MS increased 32-fold after EBV infection, with no comparable jump after other viruses, including cytomegalovirus (Bjornevik et al., 2022). Neurofilament light chain, a marker of neuroaxonal damage, rose only after EBV seroconversion; the virus came first. The authors named EBV the leading cause of MS (Bjornevik et al., 2022). Recent work centers on molecular mimicry, where antibodies and T cells aimed at the EBV nuclear antigen EBNA1 cross-react with CNS proteins like GlialCAM (Soldan & Lieberman, 2023) and this EBV reactivity has been mapped across a spectrum of conditions including lupus, RA, IBD, and Type 1 diabetes (Soldan & Lieberman, 2023).

EBV shows up in the thyroid, too. In surgical specimens, EBV proteins are found in the thyroid tissue and infiltrating lymphocytes of Hashimoto’s patients, where viral latent proteins mimic thyroid autoantigens and drive anti-TPO and anti-thyroglobulin antibody production through molecular mimicry (Wang et al., 2025). So, when I see lupus, Hashimoto’s, or MS, EBV is on my list, and in a chronically stressed patient, I’m thinking reactivation, not just past exposure.

Bacteria and the Tick-Borne Piece

Bacteria drive autoimmunity through the same mechanisms, with molecular mimicry usually at the center. Lyme disease is the clearest example I work with. Roughly 60% of untreated patients develop arthritis that can drag on for years, and cross-reactive responses to Borrelia surface proteins are well documented in antibiotic-refractory Lyme arthritis (Doskaliuk & Zimba, 2024). In a predisposed patient, Borrelia can help trigger conditions such as RA, SLE, and scleroderma through molecular mimicry (Doskaliuk & Zimba, 2024), which is why I run a full tick-borne workup, co-infections included, when someone presents with new inflammatory arthritis or shifting markers.

Campylobacter jejuni is the classic antecedent to Guillain-Barré syndrome; it carries ganglioside-like epitopes that provoke autoantibodies against peripheral nerve targets, and it is a well-established antecedent trigger through this mimicry (Suliman, 2024). Group A strep is another textbook mimic after the initial infection, the antibodies can turn on the kidneys, heart, skin, brain, or joints, producing rheumatic fever, glomerulonephritis, Sydenham chorea, and the pediatric picture we call PANDAS (Suliman, 2024). And the gut gram-negatives round it out: Klebsiella mimics HLA-B27 and links to ankylosing spondylitis, while Proteus mirabilis often through a UTI, ties to rheumatoid arthritis through cross-reactivity between bacterial and RA-targeted tissue antigens (Suliman, 2024).

COVID, Long-Haulers, and the New Wave

The pandemic gave us a real-time demonstration of everything above, and the epidemiology has caught up to the case reports. A 2025 meta-analysis pooling seventeen cohorts found COVID-19 associated with a 49% higher risk of new-onset autoimmune rheumatic disease (Peng et al., 2025). A matched analysis of over 640,000 infected patients in Germany found a 42.6% higher likelihood of developing an autoimmune disease in the post-acute window, highest for vasculitis (Tesch et al., 2023).

The mechanism is familiar. Severe COVID can set off a cytokine storm and a procoagulant state, with autoantibodies showing up frequently including ANA and neutralizing antibodies against type-I interferons (Liu et al., 2021). Cross-reactivity studies have mapped extensive molecular mimicry between the SARS-CoV-2 proteome and human autoantigens like thyroid peroxidase, myelin basic protein, and glutamic acid decarboxylase (Arévalo-Cortés et al., 2024). The long-hauler patients are the ones I watch most closely: so many show reactivated dormant infections like EBV, CMV, Mycoplasma, alongside re-elevated inflammatory markers. 

Why the Gut Is Always in the Conversation

None of this happens in isolation from the gut. The literature now firmly positions the microbiome as the mediator between infection, environmental exposure, and autoimmunity. Dysbiosis feeds the process through depleted short-chain fatty acids, a tipped Th17/regulatory T-cell balance, increased intestinal permeability with bacterial translocation, and molecular mimicry by bacterial peptides. The metabolites our microbes make directly shape regulatory T-cell differentiation, and when they drop, the immune system tilts toward the Th17-dominant, inflammatory state we see in RA, SLE, MS, type 1 diabetes, and IBD (Zhang et al., 2025). This is why barrier repair and microbial restoration are critically important.

The Serology I Actually Order

The single most important habit here is this: always consider infection in the autoimmune patient. Look past the standard autoimmune panel to the infectious drivers that may be sustaining the whole thing, and track infection titers alongside autoimmune markers over time so you can measure your treatment against both. My baseline captures conventional immune status and integrative nutritional context together, and I want to be specific about what goes on the lab requisition and why.

• Complete blood count with differential. This is my starting point, lymphopenia, atypical lymphocytes, eosinophilia, and neutrophil patterns each tell a different story, and the differential often flags a smoldering viral or parasitic process before anything else does. Inflammatory markers, e.g. CRP and ESR. CRP and hsCRP are my sensitive read on low-grade systemic inflammation; ESR is slower but useful for tracking. I trend both against symptoms and infection titers rather than reading either in isolation.
• Iron studies and ferritin — and this is where clinicians get tripped up. Ferritin is not just an iron-storage number. It is an acute-phase reactant and an active immune signaling molecule, capable of both pro-inflammatory and immunosuppressive activity, and it is directly implicated in the pathogenesis of autoimmune conditions (Mahroum et al., 2022). That dual identity is exactly the clinical trap. A patient can be genuinely iron-deficient while inflammation props her ferritin into the “normal” range so a ferritin of 45 in a systemically inflamed autoimmune patient can still mean depleted stores. This is why I never read ferritin alone. I pair it with serum iron, TIBC, and transferrin saturation, and I interpret the whole panel in the context of the CRP. Iron deficiency itself impairs immunity, lowers IgG, blunts neutrophil oxidative burst, and reduces phagocytic activity, so correcting a true deficiency is part of restoring immune competence. At the other end, a markedly elevated ferritin in the right clinical picture points me toward the hyperferritinemic syndromes and warrants a closer look.
• Vitamin D (25-OH). A critical immunomodulator; I target the upper end of the reference range in autoimmune patients, at minimum above 40 ng/mL. 
• Zinc and copper. Zinc is essential for T-cell maturation and barrier function, and I check copper alongside it because supplementation can drive the two out of balance. 
• Selenium. Beyond its general antioxidant role, selenium earns its place in autoimmune thyroid disease specifically: a meta-analysis of randomized trials found that supplementation significantly lowered thyroid peroxidase antibody levels in Hashimoto’s patients (Huwiler et al., 2024). 
• Quantitative immunoglobulins (IgG, IgA, IgM). These tell me whether the humoral system is competent, exhausted, or skewed; low IgA in particular flags mucosal vulnerability, and a low total IgG changes how aggressively I’ll pursue infection.
• The autoimmune panel and the infectious panel, run together. When the picture points to autoimmunity, I add ANA with reflex titer and pattern, rheumatoid factor, anti-CCP, and disease-specific antibodies as indicated. But I run these alongside targeted infectious testing; EBV titers (VCA IgG/IgM, EBNA, and early antigen when I’m chasing reactivation), Lyme with Western blot and co-infections, Mycoplasma, and CMV because in these patients the two panels are one story. When I suspect cross-reactivity, I’ll go looking in the literature for the specific molecular mimicry tied to the condition I’m treating, and I’ll add stool and microbiome testing, zonulin, and cytokine panels when the case calls for a deeper evaluation.

Treatment: Restore Tolerance

My approach works two fronts at once: bring down the infectious and inflammatory burden while rebuilding the tolerance and barrier integrity that broke down in the first place. Suppression alone doesn’t get a patient to lasting recovery. 

Several nutrients carry real immunomodulatory weight, and they connect directly to the serology above. Vitamin D pushes T-cell responses toward tolerance, and low serum 25(OH)D is now considered a risk factor for RA, SLE, and systemic sclerosis (Cutolo et al., 2023). Vitamin A, through its metabolite retinoic acid, supports regulatory T-cell differentiation and mucosal immunity. Zinc drives innate immunity and supports neutrophil and NK cell function, and supplementation has been shown to raise CD4+ T-cell counts and lower inflammatory markers (Wessels et al., 2024). Iron repletion, when studies confirm a true deficiency, restores the neutrophil and antibody function that iron-deficient patients lose, but I correct it carefully against the full iron panel, since free iron can feed both pathogens and oxidative stress. Selenium supports the antioxidant glutathione peroxidase system and lowers thyroid antibodies in Hashimoto’s (Huwiler et al., 2024). Alpha-lipoic acid adds antioxidant and neuroprotective activity useful in the post-infectious state, in part by regenerating glutathione and other antioxidants (Superti & Russo, 2024).

Because the gut holds so much of the immune system, barrier repair is foundational. I sequence it deliberately, remove the triggers, restore digestive sufficiency, reinoculate with beneficial microbes, repair the mucosa with L-glutamine, zinc carnosine, omega-3s, quercetin, and curcumin, and rebalance through sleep, stress work, and movement rather than layering ten things at once. And the foundations are not optional: sleep, moderate exercise that lifts NK cell activity, and stress-modulation that lowers IL-6 and CRP all regulate immunity through circadian, neuroendocrine, and autonomic pathways. Lowering infectious burden up front is legitimate prevention.

Conclusion

Post-infection autoimmunity isn’t a coincidence. A pathogen breaks tolerance through molecular mimicry, bystander activation, or epitope spreading; inflammation and dysbiosis fail to resolve; and self-reactive lymphocytes settle in to do lasting damage. The past few years have carried this model from association to cause, the 32-fold EBV-attributable risk for MS, the large post-COVID cohorts, while sharpening how we read the gut and the serology in the middle of it. Take infections seriously, screen for it, including the iron, ferritin, and nutrient status most panels overlook. Track it alongside the autoimmune markers. And build a plan that lowers the pathogen and inflammatory load while patiently restoring the barrier and the tolerance that define real health. 

References

1. Arévalo-Cortés A, Rodriguez-Pinto D, Aguilar-Ayala L. Evidence for molecular mimicry between SARS-CoV-2 and human antigens: implications for autoimmunity in COVID-19. Autoimmune Dis. 2024;2024:8359683. doi:10.1155/2024/8359683
2. Bjornevik K, Cortese M, Healy BC, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022;375(6578):296-301. doi:10.1126/science.abj8222
3. Cutolo M, Smith V, Paolino S, Gotelli E. Involvement of the secosteroid vitamin D in autoimmune rheumatic diseases and COVID-19. Nat Rev Rheumatol. 2023;19(5):265-287. doi:10.1038/s41584-023-00944-2
4. Doskaliuk B, Zimba O. Borrelia burgdorferi and autoimmune mechanisms: implications for mimicry, misdiagnosis, and mismanagement in Lyme disease and autoimmune disorders. Rheumatol Int. 2024;44(11):2265-2271. doi:10.1007/s00296-024-05580-x
5. Huwiler VV, Maissen-Abgottspon S, Stanga Z, et al. Selenium supplementation in patients with Hashimoto thyroiditis: a systematic review and meta-analysis of randomized clinical trials. Thyroid. 2024;34(3):295-313. doi:10.1089/thy.2023.0556
6. Liu Y, Sawalha AH, Lu Q. COVID-19 and autoimmune diseases. Curr Opin Rheumatol. 2021;33(2):155-162. doi:10.1097/BOR.0000000000000776
7. Mahroum N, Alghory A, Kiyak Z, et al. Ferritin — from iron, through inflammation and autoimmunity, to COVID-19. J Autoimmun. 2022;126:102778. doi:10.1016/j.jaut.2021.102778
8. Peng K, Li X, Yang D, et al. Association between COVID-19 and new-onset autoimmune diseases: updated systematic review and meta-analysis of 97 million individuals. Clin Rev Allergy Immunol. 2025;69(1):5. doi:10.1007/s12016-025-09124-4
9. Soldan SS, Lieberman PM. Epstein-Barr virus and multiple sclerosis. Nat Rev Microbiol. 2023;21(1):51-64. doi:10.1038/s41579-022-00770-5
10. Suliman BA. Potential clinical implications of molecular mimicry-induced autoimmunity. Immun Inflamm Dis. 2024;12(2):e1178. doi:10.1002/iid3.1178
11. Superti F, Russo R. Alpha-lipoic acid: biological mechanisms and health benefits. Antioxidants (Basel). 2024;13(10):1228. doi:10.3390/antiox13101228
12. Tesch F, Ehm F, Vivirito A, et al. Incident autoimmune diseases in association with SARS-CoV-2 infection: a matched cohort study. Clin Rheumatol. 2023;42(10):2905-2914. doi:10.1007/s10067-023-06670-0
13. Wang Z, Chang X, Cheng X. Epstein-Barr virus in thyroid disease: an integrated immunovirological perspective. Front Immunol. 2025;16:1687214. doi:10.3389/fimmu.2025.1687214
14. Wessels I, Rink L, et al. Dietary and physiological effects of zinc on the immune system. Annu Rev Nutr. 2024;44:1-21. doi:10.1146/annurev-nutr-122019-120635
15. Zhang F, Liu Z, Deng S, et al. Gut microbiota-derived metabolites modulate Treg/Th17 balance: novel therapeutic targets in autoimmune diseases. Front Immunol. 2025;16:1710733. doi:10.3389/fimmu.2025.1710733

Author’s Bio:

Dr. Jaquel Patterson is a nationally recognized leader in naturopathic and functional medicine and founder of Fairfield Family Health in Connecticut. With over 16 years of experience, she specializes in integrative psychiatry, Lyme disease, autoimmune conditions, and complex chronic illness. She is a three-time bestselling author, Forbes contributor, sought-after speaker and educator.

Author: NDNR-emmabelle-2026.